Akari Therapeutics Presents Positive Preclinical Data for AKTX-101
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Should l Buy AKTX?
Akari Therapeutics announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research, AACR, Annual Meeting 2026. Unlike current TROP2-targeting ADCs that use Topoisomerase I Inhibitor payloads, AKTX-101 has the potential to address resistance to Topoisomerase I Inh. ADCs and contribute to durable anti-tumor efficacy due to the payload's unique cytotoxic and immune-activating mechanisms of action. The preclinical data compares the performance of AKTX-101 versus TROP2 ADCs with Topoisomerase I Inh. payloads in the killing of different cancer types driven by different cancer genes. AKTX-101's ability to kill cancer cells at lower concentrations vs. TROP2 ADCs using Topoisomerase I Inh. payloads suggests that AKTX-101 is a more potent drug.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.800
Low
1.00
Averages
3.33
High
7.00
Current: 5.800
Low
1.00
Averages
3.33
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Akari Therapeutics Showcases Potent Efficacy of AKTX-101
- Preclinical Data Breakthrough: Akari Therapeutics presented positive preclinical data for its TROP2-targeting ADC, AKTX-101, at the 2026 AACR Annual Meeting, demonstrating superior efficacy compared to existing Topoisomerase I inhibitor payloads across bladder, lung, and breast cancer models, indicating its potential in anti-tumor therapy.
- Resistance Overcoming Potential: The unique RNA splicing modulator payload of AKTX-101 shows promise in overcoming resistance to Topoisomerase I inhibitors, exhibiting potent cancer cell killing at lower concentrations, thereby offering patients more durable anti-tumor effects.
- Broad Market Prospects: With the TROP2 ADC market projected to reach approximately $12 billion by 2033, AKTX-101's innovative payload is expected to further drive market growth, particularly across various tumor types including bladder, lung, and breast cancers.
- Clinical Trial Plans: Akari plans to submit an IND application in Q4 2026 and initiate Phase 1 clinical trials for AKTX-101 in Q1 2027, demonstrating the company's commitment and capability in rapidly advancing clinical development.
See More
Akari Therapeutics Presents Positive Preclinical Data for AKTX-101
- Positive Preclinical Data: Akari Therapeutics presented promising preclinical data for AKTX-101 at the 2026 AACR annual meeting, indicating significant anti-tumor effects across various cancer indications, potentially offering new hope in cancer treatment.
- Unique Mechanism of Action: By targeting TROP2 and incorporating Topoisomerase 1 inhibitors, AKTX-101 exhibits a unique cytotoxic and immune-activating mechanism, demonstrating enhanced durability in anti-tumor efficacy, particularly against resistant cancer cells.
- Strong Potency: In non-small cell lung cancer cell lines, AKTX-101 showed sub-nanomolar potency, significantly outperforming existing TROP2 ADCs, highlighting its potential in treating bladder, lung, and breast cancers.
- Future Development Plans: The company anticipates submitting an investigational new drug application in Q4 2026 and plans to initiate a Phase 1 trial by early 2027, with projections indicating the TROP2 ADC market could reach $12 billion by 2033, allowing for expansion into various solid tumors.
See More
Akari Therapeutics Partners with WuXi XDC to Advance PH1 Payload Development
- Strategic Partnership: Akari Therapeutics has formed a strategic partnership with WuXi XDC to accelerate the development of its proprietary PH1 payload, which is expected to support Akari's IND filing by late 2026 and advance its lead program AKTX-101, initially targeting metastatic urothelial cancer.
- Innovative Drug Platform: The PH1 payload represents a differentiated ADC approach designed to disrupt RNA splicing in cancer cells, offering direct cytotoxicity while activating both innate and adaptive immune responses, and has shown superior tumor regression and complete remissions compared to traditional ADCs, highlighting its potential as a next-generation therapy.
- Clinical Trial Plans: A Phase 1 clinical trial for AKTX-101 is anticipated to begin in late 2026 or early 2027, subject to regulatory clearance, which will lay the groundwork for Akari's further expansion in oncology treatment.
- Market Dynamics: Akari implemented a 1-for-40 reverse stock split on March 30, 2026; despite closing at $3.54 on Monday, down 20.81%, the stock rebounded to $3.60 in overnight trading, reflecting a 1.69% increase.
See More
Akari Partners with WuXi to Accelerate Cancer Drug Development
- Partnership to Accelerate Development: Akari Therapeutics has partnered with WuXi Biologics' subsidiary WuXi XDC to leverage their expertise in antibody-drug conjugate (ADC) manufacturing, aiming to accelerate the development of its new cancer drug component, PH1, which is expected to significantly shorten the R&D timeline.
- Clinical Trial Plans: This collaboration supports Akari's lead program, AKTX-101, which is anticipated to enter Phase 1 trials by late 2026 or early 2027, pending approval, bringing its next-generation cancer therapies closer to market.
- Stock Price Impact: Following this announcement, Akari Therapeutics' stock fell by 21.65% to $3.50 in intraday trading, reflecting market concerns over its R&D progress, which may affect investor confidence.
- Market Outlook Analysis: By partnering with WuXi, Akari not only enhances the development efficiency of its ADC pipeline but also positions itself more favorably in the competitive cancer treatment market, potentially strengthening its long-term growth prospects.
See More
Akari Therapeutics Adjusts ADS Ratio to Meet Nasdaq Requirements
- ADS Ratio Change: Akari Therapeutics is changing its American Depositary Shares (ADS) ratio from 1:2,000 to 1:80,000 effective March 31, 2026, aimed at meeting Nasdaq's minimum bid price requirements to ensure continued listing.
- Shareholder Exchange Mechanism: Under the revised structure, shareholders will exchange 40 existing ADS for 1 new ADS, which is expected to elevate the per-share price, enhance investor confidence, and attract more institutional investors.
- Ordinary Shares Unchanged: Despite the change in ADS ratio, the company's underlying ordinary shares remain unchanged, indicating that the company's fundamentals are not directly impacted, which may preserve investor perceptions of long-term value.
- Positive Market Reaction: Following the announcement of the adjustment, Akari Therapeutics' shares rose by 4.2% in after-hours trading, reflecting a positive market response to this strategic adjustment and potentially signaling investor optimism about the company's future prospects.
See More
Akari Therapeutics Appoints New Scientific Advisor to Advance AKTX-101
- New Scientific Advisor: Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, leveraging his extensive experience in experimental therapeutics and translational oncology to enhance the development of AKTX-101, which is expected to improve the likelihood of successful product advancement.
- Clinical Trial Advancement: Dr. Gokhale's expertise comes at a pivotal time as AKTX-101 progresses toward clinical trials, and his insights will help ensure the drug enters the clinic with a focused, data-driven high-impact program to optimize therapeutic outcomes.
- Unique Drug Mechanism: The novel PH1 payload of AKTX-101 targets RNA splicing, offering a different mechanism compared to traditional antibody-drug conjugates, potentially disrupting tumor survival pathways while enhancing immune system engagement.
- Future Outlook: Akari aims to initiate its First-In-Human trial for AKTX-101 by late 2026 to early 2027, and Dr. Gokhale's involvement is expected to accelerate this process, bolstering the company's competitiveness in oncology drug development.
See More
Akari Therapeutics Showcases Potent Efficacy of AKTX-101
- Preclinical Data Breakthrough: Akari Therapeutics presented positive preclinical data for its TROP2-targeting ADC, AKTX-101, at the 2026 AACR Annual Meeting, demonstrating superior efficacy compared to existing Topoisomerase I inhibitor payloads across bladder, lung, and breast cancer models, indicating its potential in anti-tumor therapy.
- Resistance Overcoming Potential: The unique RNA splicing modulator payload of AKTX-101 shows promise in overcoming resistance to Topoisomerase I inhibitors, exhibiting potent cancer cell killing at lower concentrations, thereby offering patients more durable anti-tumor effects.
- Broad Market Prospects: With the TROP2 ADC market projected to reach approximately $12 billion by 2033, AKTX-101's innovative payload is expected to further drive market growth, particularly across various tumor types including bladder, lung, and breast cancers.
- Clinical Trial Plans: Akari plans to submit an IND application in Q4 2026 and initiate Phase 1 clinical trials for AKTX-101 in Q1 2027, demonstrating the company's commitment and capability in rapidly advancing clinical development.
See More
Akari Therapeutics Presents Positive Preclinical Data for AKTX-101
- Positive Preclinical Data: Akari Therapeutics presented promising preclinical data for AKTX-101 at the 2026 AACR annual meeting, indicating significant anti-tumor effects across various cancer indications, potentially offering new hope in cancer treatment.
- Unique Mechanism of Action: By targeting TROP2 and incorporating Topoisomerase 1 inhibitors, AKTX-101 exhibits a unique cytotoxic and immune-activating mechanism, demonstrating enhanced durability in anti-tumor efficacy, particularly against resistant cancer cells.
- Strong Potency: In non-small cell lung cancer cell lines, AKTX-101 showed sub-nanomolar potency, significantly outperforming existing TROP2 ADCs, highlighting its potential in treating bladder, lung, and breast cancers.
- Future Development Plans: The company anticipates submitting an investigational new drug application in Q4 2026 and plans to initiate a Phase 1 trial by early 2027, with projections indicating the TROP2 ADC market could reach $12 billion by 2033, allowing for expansion into various solid tumors.
See More
Akari Therapeutics Partners with WuXi XDC to Advance PH1 Payload Development
- Strategic Partnership: Akari Therapeutics has formed a strategic partnership with WuXi XDC to accelerate the development of its proprietary PH1 payload, which is expected to support Akari's IND filing by late 2026 and advance its lead program AKTX-101, initially targeting metastatic urothelial cancer.
- Innovative Drug Platform: The PH1 payload represents a differentiated ADC approach designed to disrupt RNA splicing in cancer cells, offering direct cytotoxicity while activating both innate and adaptive immune responses, and has shown superior tumor regression and complete remissions compared to traditional ADCs, highlighting its potential as a next-generation therapy.
- Clinical Trial Plans: A Phase 1 clinical trial for AKTX-101 is anticipated to begin in late 2026 or early 2027, subject to regulatory clearance, which will lay the groundwork for Akari's further expansion in oncology treatment.
- Market Dynamics: Akari implemented a 1-for-40 reverse stock split on March 30, 2026; despite closing at $3.54 on Monday, down 20.81%, the stock rebounded to $3.60 in overnight trading, reflecting a 1.69% increase.
See More
Akari Partners with WuXi to Accelerate Cancer Drug Development
- Partnership to Accelerate Development: Akari Therapeutics has partnered with WuXi Biologics' subsidiary WuXi XDC to leverage their expertise in antibody-drug conjugate (ADC) manufacturing, aiming to accelerate the development of its new cancer drug component, PH1, which is expected to significantly shorten the R&D timeline.
- Clinical Trial Plans: This collaboration supports Akari's lead program, AKTX-101, which is anticipated to enter Phase 1 trials by late 2026 or early 2027, pending approval, bringing its next-generation cancer therapies closer to market.
- Stock Price Impact: Following this announcement, Akari Therapeutics' stock fell by 21.65% to $3.50 in intraday trading, reflecting market concerns over its R&D progress, which may affect investor confidence.
- Market Outlook Analysis: By partnering with WuXi, Akari not only enhances the development efficiency of its ADC pipeline but also positions itself more favorably in the competitive cancer treatment market, potentially strengthening its long-term growth prospects.
See More
Akari Therapeutics Adjusts ADS Ratio to Meet Nasdaq Requirements
- ADS Ratio Change: Akari Therapeutics is changing its American Depositary Shares (ADS) ratio from 1:2,000 to 1:80,000 effective March 31, 2026, aimed at meeting Nasdaq's minimum bid price requirements to ensure continued listing.
- Shareholder Exchange Mechanism: Under the revised structure, shareholders will exchange 40 existing ADS for 1 new ADS, which is expected to elevate the per-share price, enhance investor confidence, and attract more institutional investors.
- Ordinary Shares Unchanged: Despite the change in ADS ratio, the company's underlying ordinary shares remain unchanged, indicating that the company's fundamentals are not directly impacted, which may preserve investor perceptions of long-term value.
- Positive Market Reaction: Following the announcement of the adjustment, Akari Therapeutics' shares rose by 4.2% in after-hours trading, reflecting a positive market response to this strategic adjustment and potentially signaling investor optimism about the company's future prospects.
See More
Akari Therapeutics Appoints New Scientific Advisor to Advance AKTX-101
- New Scientific Advisor: Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, leveraging his extensive experience in experimental therapeutics and translational oncology to enhance the development of AKTX-101, which is expected to improve the likelihood of successful product advancement.
- Clinical Trial Advancement: Dr. Gokhale's expertise comes at a pivotal time as AKTX-101 progresses toward clinical trials, and his insights will help ensure the drug enters the clinic with a focused, data-driven high-impact program to optimize therapeutic outcomes.
- Unique Drug Mechanism: The novel PH1 payload of AKTX-101 targets RNA splicing, offering a different mechanism compared to traditional antibody-drug conjugates, potentially disrupting tumor survival pathways while enhancing immune system engagement.
- Future Outlook: Akari aims to initiate its First-In-Human trial for AKTX-101 by late 2026 to early 2027, and Dr. Gokhale's involvement is expected to accelerate this process, bolstering the company's competitiveness in oncology drug development.
See More
